[CHAOS]

5TH JUL 2021

The Health Sciences Authority (HSA) is still awaiting additional data to complete its evaluation of the Sinovac-CoronaVac vaccine for its safety and efficacy standards.  The vaccine is therefore not yet authorised for use by HSA under the Pandemic Special Access Route (PSAR), and is not recommended as part of the national vaccination programme by the Expert Committee on COVID-19 Vaccination.  Hence, individuals should be aware that they will not be eligible for the Vaccine Injury Financial Assistance Programme (VIFAP) should any serious side effects occur.  Only a small group of persons would be contraindicated for the mRNA vaccines.  These include (i) persons who had allergic reactions to the first dose of mRNA-based vaccine, and (ii) persons who are allergic to other vaccines and are assessed by an allergist to be unsuitable for mRNA-based vaccines.  For these persons, MOH has ringfenced sufficient Sinovac-CoronaVac vaccine stocks for their priority use.

https://www.moh.gov.sg/news-highlights/d...programme/